1. Search Result
Search Result
Results for "

293t cell and akt Inhibitors

" in MedChemExpress (MCE) Product Catalog:

9565

Inhibitors & Agonists

180

Screening Libraries

531

Fluorescent Dye

288

Biochemical Assay Reagents

877

Peptides

95

MCE Kits

305

Inhibitory Antibodies

1740

Natural
Products

1357

Recombinant Proteins

357

Isotope-Labeled Compounds

229

Antibodies

59

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-138102

    SARS-CoV Infection
    SSAA09E3 is a SARS-CoV entry inhibitor that inhibits SARS/HIV pseudotyped virus entry with an EC50 of 9.7 μM in 293T cells and inhibits SARS-CoV infection of Vero cells with an EC50 of 0.15 μM .
    SSAA09E3
  • HY-120210

    ROR Inflammation/Immunology Cancer
    XY018 is a potent ROR-γ-selective antagonist. XY018 inhibits ROR-γ constitutive activity in 293T cells with high potency (EC50, 190 nM). XY018 binds to the ROR-γ hydrophobic ligand binding domain (LBD) .
    XY018
  • HY-145879

    Keap1-Nrf2 Cancer
    Nrf2 activator-2 (compound O15), a Osthole derivative, is a potent Nrf2 agonist with an EC50 of 2.9 μM in 293 T cells. Nrf2 activator-2 effectively inhibits the interaction between Keap1 and Nrf2, thus showing the activation effect on Nrf2. Nrf2 activator-2 shows a marked decrease in the level of ubiquitinated Nrf2 in cells .
    Nrf2 activator-2
  • HY-158201

    Others Neurological Disease
    ATF4-IN-1 (Compound 21) is an ATF4 inhibitor. ATF4-IN-1 inhibits ATF4 expression in Thapsigargin (HY-13433)-stimulated HEK-293T cells, with an IC50 value of 32.43 nM. ATF4-IN-1 is more active than ISRIB (HY-12495A). ATF4-IN-1 exhibits low cytotoxicity (IC50: 96 μM against HEK-293T cells). ATF4-IN-1 can be used for research of neurodegenerative diseases .
    ATF4-IN-1
  • HY-158058

    Toll-like Receptor (TLR) Pyroptosis Inflammation/Immunology Cancer
    WYJ-2 is a selective agonist for toll-like receptor 2/1 (TLR2/1) with EC50 of 18.57 nM in human TLR2 and TLR1 transient-cotransfected HEK 293T cells. WYJ-2 induces pyroptosis and exhibits anticancer activity against non-small cell lung cancer (NSCLC) .
    WYJ-2
  • HY-101775A

    Topoisomerase Cardiovascular Disease Cancer
    9-Hydroxyellipticine hydrochloride is a inhibitor of Topo II and RyR. 9-Hydroxyellipticine hydrochloride exhibits antitumor, antioxidant and catecholamine-releasing activities. 9-Hydroxyellipticine hydrochloride exhibits IC50 values of 1.6 μM and 1.2μM in Hela S-3 and 293T cells, respectively .
    9-Hydroxyellipticine hydrochloride
  • HY-N0041

    Gypenoside IV

    NF-κB COX NO Synthase Inflammation/Immunology Cancer
    Ginsenoside Rb3 is extracted from steamed Panax ginseng C. A. Meyer. Ginsenoside Rb3 exhibits inhibitory effect on TNFα-induced NF-κB transcriptional activity with an IC50 of 8.2 μM in 293T cell lines. Ginsenoside Rb3 also inhibits the induction of COX-2 and iNOS mRNA.
    Ginsenoside Rb3
  • HY-158342

    PROTACs YAP Cancer
    PROTAC TEAD degrader-1 (Compound 27) is a PROTAC degrader for transcriptional enhanced associate domain (TEAD). PROTAC TEAD degrader-1 selectively degrades the Flag TEAD2 in a ubiquitin proteasome-dependent manner, with a DC50 of 54.1 nM in 293T cells, inhibits proliferation of NF2-deficient NCI-H226 with an IC50 of 0.21 μM, and regulates expressions of yes associated protein (YAP) target genes. (Pink: TEAD ligand (HY-158400); Black: linker (HY-W008474); Blue: E3 ligase ligand (HY-W087383))
    PROTAC TEAD degrader-1
  • HY-N0041R

    Gypenoside IV (Standard)

    NF-κB COX NO Synthase Inflammation/Immunology Cancer
    Ginsenoside Rb3 (Standard) is the analytical standard of Ginsenoside Rb3. This product is intended for research and analytical applications. Ginsenoside Rb3 is extracted from steamed Panax ginseng C. A. Meyer. Ginsenoside Rb3 exhibits inhibitory effect on TNFα-induced NF-κB transcriptional activity with an IC50 of 8.2 μM in 293T cell lines. Ginsenoside Rb3 also inhibits the induction of COX-2 and iNOS mRNA.
    Ginsenoside Rb3 (Standard)
  • HY-149359

    Isocitrate Dehydrogenase (IDH) Cancer
    IHMT-IDH1-053 (compound 16) is a highly selectivity and irreversible IDH1-mutant inhibitor with an IC50 of 4.7 nM for IDH1 R132H. IHMT-IDH1-053 displays high selectivity against IDH1 mutants over IDH1 wt and IDH2 wt/mutants. IHMT-IDH1-053 inhibits 2-hydroxyglutarate (2-HG) production in IDH1 R132H mutant transfected 293T cells (IC50=28 nM). IHMT-IDH1-053 binds to the IDH1 R132H protein in the allosteric pocket adjacent to the NAPDH binding pocket through a covalent bond with residue Cys269. IHMT-IDH1-053 inhibits the proliferation of HT1080 cell line and primary AML cells which both bear IDH1 R132 mutants .
    IHMT-IDH1-053
  • HY-149841

    Akt Cancer
    AKT-IN-17 is a AKt inhibitor. AKT-IN-17 inhibits AKt in A549 cells, leading to Apoptosis. AKT-IN-17 can be used in non-small cell lung cancer study .
    <em>AKT</em>-IN-17
  • HY-149842

    Akt Apoptosis Cancer
    AKT-IN-18, an inhibitor of Akt, inhibits Akt with an IC50 of 69.45 μΜ in A549 cells. AKT-IN-18 induces apoptosis and can be used in non-small cell lung cancer study .
    <em>AKT</em>-IN-18
  • HY-144059

    Akt Cancer
    AKT-IN-9 is a potent inhibitor of AKT. Protein kinase B (PKB, also known as AKT) is central to PI3K/AKT/mTOR signaling in cells, and its function is important for cell growth, survival, differentiation and metabolism. AKT-IN-9 has the potential for the research of breast and prostate cancer (extracted from patent WO2021185238A1, compound 1) .
    <em>AKT</em>-IN-9
  • HY-144060

    Akt Cancer
    AKT-IN-10 is a potent inhibitor of AKT. Protein kinase B (PKB, also known as AKT) is central to PI3K/AKT/mTOR signaling in cells, and its function is important for cell growth, survival, differentiation and metabolism. AKT-IN-10 has the potential for the research of breast and prostate cancer (extracted from patent WO2021185238A1, compound 4) .
    <em>AKT</em>-IN-10
  • HY-P10049

    Akt Cancer
    TAT-TCL1-Akt-in is an Akt inhibitor .
    TAT-TCL1-<em>Akt</em>-in
  • HY-154960

    Akt Apoptosis Microtubule/Tubulin Cancer
    Tubulin/AKT1-IN-1 (Compound D1-1) is an inhibitor of tubulin polymerization and AKT pathway activation. Tubulin/AKT1-IN-1 significantly inhibits the proliferation and metastasis of H1975 cells and slightly induced their apoptosis and can be used for non-small-cell lung cancer (NSCLC) research .
    Tubulin/<em>AKT</em>1-IN-1
  • HY-148868A

    Akt CDK Cancer
    Akt1&PKA-IN-2 ((R)-29) is an inhibitor of PKB/AKT with cyclin-dependent kinase 2 (CDK2) selectivity. Akt1&PKA-IN-2 inhibits AKT1, PKAa and CDK2 a with IC50 values of 0.007 µM, 0.01 µM and 0.69 µM, respectively .
    <em>Akt</em>1&PKA-IN-2
  • HY-161351

    Akt STAT Apoptosis Cancer
    STAT3/AKT-IN-1 is a dual inhibitor for the signal transducer and activator of transcription 3 (STAT3) and protein kinase B (AKT) signalling pathway, exhibits antitumor activity against gastric cancer and induces cell apoptosis in SGC-7901 cells .
    STAT3/<em>AKT</em>-IN-1
  • HY-145244

    Akt Cancer
    APN/AKT-IN-1 is a potent and dual inhibitor of APN and AKT with IC50s of 0.21 and 0.27 μM, respectively. APN/AKT-IN-1 can effectively inhibit the phosphorylation of GSK3β, the intracellular substrate of AKT .
    APN/<em>AKT</em>-IN-1
  • HY-14971
    (E)-Akt inhibitor-IV
    1 Publications Verification

    (E)-aktIV

    Akt Cancer
    (E)-Akt inhibitor-IV ((E)-AKTIV) is a PI3K-Akt inhibitor, with potent cytotoxic .
    (E)-<em>Akt</em> inhibitor-IV
  • HY-129119

    Akt Caspase Cancer
    Akt1/Akt2-IN-2 (compound 7) is an allosteric dual Akt1 and Akt2 inhibitor (IC50=138 nM and 212 nM, respectively). Akt1/Akt2-IN-2 increases activity of caspase-3, and inhibits viability of a number of tumor cells .
    <em>Akt</em>1/<em>Akt</em>2-IN-2
  • HY-161144

    Akt Apoptosis Cancer
    AKT-IN-21 (compound C36) is a potent AKT inhibitor with broad-spectrum cytotoxicity and anticancer activity. AKT-IN-21 also blocks the cell cycle and induces apoptosis of cancer cells by down-regulating the PI3K/AKT pathway .
    <em>AKT</em>-IN-21
  • HY-161439

    Akt Cancer
    Akt1-IN-4 (Compound 62) is an AKT1-E17K inhibitor with an IC50 value of less than 15 nM .
    <em>Akt</em>1-IN-4
  • HY-163511

    Akt Apoptosis mTOR PI3K Microtubule/Tubulin Cancer
    PI3K/Akt/mTOR-IN-4 (compound 4r) is a potent PI3K/Akt/mTOR and tubulin polymerization inhibitor. PI3K/Akt/mTOR-IN-4 induce apoptosis and cell cycle arrest at G2/M phase. PI3K/Akt/mTOR-IN-4 decreases the expression of p-PI3K, p-Akt, and p-mTOR, β-tubulin .
    PI3K/<em>Akt</em>/mTOR-IN-4
  • HY-147513

    Akt Apoptosis Cancer
    AKT-IN-12 (compound 3e) is a potent Akt kinase inhibitor with an IC50 value of 0.55 μM. AKT-IN-12 induces G0/G1 cell cycle arrest and apoptosis. AKT-IN-12 also inhibits p-AKT, p-ERK, and activates p-JNK, JNK. AKT-IN-12 can be used for researching leukemia .
    <em>AKT</em>-IN-12
  • HY-146459

    Akt Cancer
    Akt1-IN-1 (compound 5b) is a potent and selective Akt1 inhibitor with an IC50 value of 18.79 nM in MIA Paca-2 cells. Akt1-IN-1 does not exhibit obvious teratogenicity, hepatotoxicity and cardiotoxicity (No Observed Adverse Effect Level > 100 µM). Akt1-IN-1 can be used for researching anticancer .
    <em>Akt</em>1-IN-1
  • HY-50862

    Akt Cancer
    Akt1/Akt2-IN-1 (Compound 17) is an allosteric inhibitor of Akt1 (IC50=3.5 nM) and Akt2 (IC50=42 nM), with potent and balanced activity .
    <em>Akt</em>1/<em>Akt</em>2-IN-1
  • HY-126257

    Akt Apoptosis Cancer
    AKT-IN-3 (compound E22) is a potent, orally active low hERG blocking Akt inhibitor, with 1.4 nM, 1.2 nM and 1.7 nM for Akt1, Akt2 and Akt3, respectively. AKT-IN-3 (compound E22) also exhibits good inhibitory activity against other AGC family kinases, such as PKA, PKC, ROCK1, RSK1, P70S6K, and SGK. AKT-IN-3 (compound E22) induces apoptosis and inhibits metastasis of cancer cells .
    <em>AKT</em>-IN-3
  • HY-146751
    PI3K/Akt/mTOR-IN-2
    2 Publications Verification

    PI3K Akt mTOR Apoptosis Cancer
    PI3K/Akt/mTOR-IN-2 is a PI3K/AKT/mTOR pathway inhibitor. PI3K/Akt/mTOR-IN-2 possess anti-cancer effects and selectivity against MDA-MB-231 cells with IC50 value of 2.29 μM. PI3K/Akt/mTOR-IN-2 can induce cancer cell cycle arrest and apoptosis .
    PI3K/<em>Akt</em>/mTOR-IN-2
  • HY-10355
    AKT inhibitor VIII
    35+ Cited Publications

    akti-1/2

    Akt Apoptosis Metabolic Disease Cancer
    AKT inhibitor VIII (AKTi-1/2) is a cell-permeable quinoxaline compound that has been shown to potently, selectively, allosterically, and reversibly inhibit Akt1, Akt2, and Akt3 activity with IC50s of 58 nM, 210 nM, and 2119 nM, respectively.
    <em>AKT</em> inhibitor VIII
  • HY-151606

    Akt Cancer
    Akt3 degrader 1 (compound 12l) is a selective Akt3 degrader that overcomes Osimertinib (HY-15772)-induced resistance in H1975OR NSCLC cells. Akt3 degrader 1 also has anti-proliferative activity and significantly inhibits tumour growth in mice. Akt3 degrader 1 can be used in the study of drug-resistant non-small cell lung cancer .
    <em>Akt</em>3 degrader 1
  • HY-19982

    Akt Cancer
    AKT-IN-6 (Example 13) is a potent Akt inhibitor. AKT-IN-6 inhibits Akt1, Akt2 and Akt3 with IC50s < 500nM, respectively. (patent WO2013056015A1).
    <em>AKT</em>-IN-6
  • HY-143611

    Akt Cancer
    AKT-IN-8 is a potent AKT inhibitor with IC50s of 4.46, 2.44, and 9.47 nM for AKT1, AKT2, and AKT3, respectively .
    <em>AKT</em>-IN-8
  • HY-138767

    Akt Cancer
    AKT-IN-5 (Example 8) is a Akt inhibitor with IC50 values of 450 nM and 400 nM for Akt1 and Akt2, respectively .
    <em>AKT</em>-IN-5
  • HY-147937

    Akt Cancer
    AKT-IN-13 (compound 4b) is a potent Akt inhibitor with IC50s of 1.6 nM, 2.4 nM and 0.3 nM for Akt1, Akt2 and Akt3, respectively. AKT-IN-13 can be used for researching anticancer .
    <em>AKT</em>-IN-13
  • HY-147913

    PI3K Akt mTOR Apoptosis Cancer
    PI3K/Akt/mTOR-IN-3 (compound 3d) is a potent PI3K/AKT/mTOR inhibitor. PI3K/Akt/mTOR-IN-3 displays the inhibitory activity in MCF-7, HeLa and HepG2 cells, with IC50 values of 0.77, 1.23, and 4.57μM, respectively. PI3K/Akt/mTOR-IN-3 inhibits the migration of MCF-7 and HeLa cells at the concentration of 4 μM. PI3K/Akt/mTOR-IN-3 induces cell apoptosis and S phase arrest .
    PI3K/<em>Akt</em>/mTOR-IN-3
  • HY-153640

    Akt Cancer
    AKT-IN-14 (Example 2) is a potent AKTinhibitor with the IC50 values of <0.01 nM, 1.06 nM and 0.66 nM for AKT1, AKT2, AKT3, respectively. AKT-IN-14 can be used in cancer research .
    <em>AKT</em>-IN-14
  • HY-161438

    Akt Cancer
    Akt1-IN-3 (Compd 7) is an inhibitor of AKT1. Akt1-IN-3 inhibits AKT1- E17K with IC50 < 15 nM .
    <em>Akt</em>1-IN-3
  • HY-112148

    Akt Cancer
    AKT-IN-2 is a potent, selective and orally bioavailable AKT inhibitor with an IC50 of 5 nM for AKT1 .
    <em>AKT</em>-IN-2
  • HY-143610

    Akt Cancer
    AKT-IN-7 (compound 1-P1) is a potent AKT inhibitor. AKT-IN-7 has the potential for cancer research .
    <em>AKT</em>-IN-7
  • HY-144253

    Akt ERK Cancer
    AKT-IN-11 is one of the most effective antibacterial agents against human hepatoma BEL-7402 cell line with an IC50 value of 1.15μM.
    <em>AKT</em>-IN-11
  • HY-163577

    Akt Cancer
    Akt1-IN-5 (Compound 115) is an Akt1 inhibitor (IC50: <15 nM)
    <em>Akt</em>1-IN-5
  • HY-163578

    Akt Cancer
    Akt1-IN-6 (Compound 273) is an Akt1 inhibitor (IC50: <15 nM)
    <em>Akt</em>1-IN-6
  • HY-163579

    Akt Cancer
    Akt1-IN-7 (Compound 370) is an Akt1 inhibitor (IC50: <15 nM) .
    <em>Akt</em>1-IN-7
  • HY-10249A
    AKT Kinase Inhibitor
    10+ Cited Publications

    Akt Cancer
    AKT Kinase Inhibitor is an Akt kinase inhibitor with anti-tumor activity .
    <em>AKT</em> Kinase Inhibitor
  • HY-18296
    AKT-IN-1
    4 Publications Verification

    Akt Cancer
    AKT-IN-1 is an allosteric AKT inhibitor with an IC50 of 1.042 μM.
    <em>AKT</em>-IN-1
  • HY-16034

    Akt Cancer
    AKT-IN-20 is an AKT inhibitor, and can be used for research of cancer
    <em>AKT</em>-IN-20
  • HY-163180

    Akt Cancer
    AKT-IN-22 (compound 0R4) is a potent AKT allosteric inhibitor with anticancer effects .
    <em>AKT</em>-IN-22
  • HY-10249D

    Akt Cancer
    AKT Kinase Inhibitor hydrochloride is an Akt kinase inhibitor with anti-tumor activity . AKT Kinase Inhibitor (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    <em>AKT</em> Kinase Inhibitor hydrochloride
  • HY-148868

    Akt PKA CDK Others
    Akt1&PKA-IN-1 is a potent dual Akt/PKA inhibitor with IC50 values of 0.03 , 0.11 μM, and 9.8 μM for PKAa, Akt, and CDK2, respectively. Akt1&PKA-IN-1 is selective for cyclin-dependent kinase 2 (CDK2) .
    <em>Akt</em>1&PKA-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: